Beijing Double-Crane Pharmaceutical Co., Ltd. was established in 1997. The major promoter to the establishment of the company is Beijing Pharmaceutical Plant, which was set up in 1939. The company's A shares were listed on Shanghai Stock Exchange on May 22, 1997. As a new & high-tech enterprise and the first approved GMP pharmaceutical company in China, the company is principally engaged in manufacture, processing and distribution of pharmaceuticals. Its products are classified into three categories: infusion solutions, cardiovascular drugs and endocrine secretion drugs, including vitamin E and C granules, ofloxacin (antimicrobial drug), levofloxacin mesylate (antimicrobial drugs) and metformin hydrochloride tablets, among others. By December 2006, it has annual sales about US$ 600 million, controlling shareholding in 17 subsidiaries and shares in 7 companies in most major cities throughout China. And its business covers areas of medical research, production, circulation and pharmaceutical equipment. DCPC has more than 10000 employees at present and a wide range of name brand products including Beijing Hypotensive No.0 Tablet, Ofloxacin, Levofloxacin, Wen Wei Shu granule, Yang Wei Shu granule, Beijing Royal Jelly etc. The company distributes its products primarily in domestic market.
Headquarters
No. 1, Lize East 2nd Road, Wangjing, Chaoyang District, Beijing
Beijing; Beijing;
Postal Code: 100102
Contact Details: Purchase the China Resources Double-Crane Pharmaceutical Co.,Ltd. report to view the information.
Website: http://www.dcpc.com
EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.
Request a demo of the EMIS serviceTo view more information, Request a demonstration of the EMIS service